Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor and Resistance-Directed Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ERBB3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ERBB3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ERBB3 Products |
| Gene Delivery | ERBB3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction in cancer models. |
View ERBB3 Products |
| Benchmark Ab | Anti-ERBB3 (Sequence of Patritumab / HER3-DXd biosimilar) Recombinant IgG1 positive control for ADC internalization assays. |
View ERBB3 Products |
| Validator | ERBB3 siRNA Set For specific knockdown verification and off-target control experiments. |
View ERBB3 Products |
| Related Target A: EGFR (HER1) | EGFR (HER1) Synergistic pathway and heterodimerization partner. |
View EGFR Products |
| Related Target B: ERBB2 (HER2) | ERBB2 (HER2) Obligate dimerization partner; heterodimerization required for oncogenic signaling. |
View ERBB2 Products |
| Related Target C: NRG1 | NRG1 (Neuregulin 1) Primary ligand driving HER3 phosphorylation; resistance mechanism target. |
View NRG1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Internalization Efficiency (ADC Development) | ECD-Fc Fusion with authentic extracellular domain boundaries (Ser23-Thr643); preserves conformational epitopes for internalization kinetics. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence homology verified by mass spectrometry. |
| Subfamily Counter Screening | Homolog panel proteins (EGFR, HER2, HER4) strictly verified by mass spec and theoretical MW. |
| Heterodimerization Blocking (Mechanism Validation) | HER2:HER3 heterodimerization assay ready; matched pair proteins for SPR/BLI affinity ranking. |
| Resistance Mutation Screening | NRG1 fusion protein and mutant HER3 variants available for resistance mechanism studies. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
Live ERBB3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HER3-targeted therapeutics is intensifying, with Daiichi Sankyo's patritumab deruxtecan (U3-1402) leading the ADC wave and Merus' zenocutuzumab pioneering the bispecific approach. As first-generation therapies demonstrate clinical efficacy in EGFR-resistant NSCLC and HER2-low breast cancer, the next wave of R&D is targeting acquired resistance mechanisms involving NRG1 fusions and HER3-activating mutations. The field is rapidly shifting from monotherapy to rational combinations, necessitating sophisticated assay systems that can quantify heterodimer disruption and internalization kinetics under therapeutic pressure.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Daiichi Sankyo, AstraZeneca, SystImmune, BioNTech | NSCLC, Breast Cancer (EGFR-TKI resistant) | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Bispecific Antibody | Merus, Elevation Oncology | Solid Tumors (NRG1 fusion+) | Heterodimer Disruption (Need HER2:HER3 complex proteins) |
| Monoclonal Antibody | ElevateBio, AVEO, Serono, Novartis | Colorectal, Ovarian Cancer | Ligand Blocking (Need NRG1 competition assays) |
| Small Molecule (Allosteric) | Various Discovery Phase | Refractory Mutants | Conformational Selectivity (Need mutant vs WT protein panels) |